A Phase II Randomized Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (GU17-289)

Study Overview

The purpose of this study is to compare any good and bad effects of using a high dose Interleukin (IL-2) and Entinostat to using IL-2 alone. The addition of Entinostat to high dose IL-2 could shrink your cancer/prevent it from returning for a longer period of time but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.

Study Description

The purpose of this study is to estimate and compare progression free survival (PFS) in patients receiving high dose interleukin 2 or high dose interleukin 2 plus entinostat.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1712301349
  • Research Study Identifier: TX8766
  • Principal Investigator: Roberto Pili, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176